[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100406917":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":36,"centralContacts":40,"locations":45,"responsibleParty":62,"collaborators":30,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":30,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":30,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":47,"whyStopped":30,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"University of Alberta","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"MET","ACTIVE_COMPARATOR","MET (850 mg po bid - standard of care) + Fiber placebo daily",[13],"Drug: Metformin 850 mg oral tablet bid",{"label":15,"type":10,"description":16,"interventionNames":17},"FIBER","Fiber supplementation \\[35g fiber daily\\] + MET placebo po bid",[18],"Dietary Supplement: Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.",{"label":20,"type":21,"description":22,"interventionNames":23},"FIBER + MET","EXPERIMENTAL","Fiber supplementation \\[35g fiber daily\\] + MET 850 mg po bid",[13,18],[25,31],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Metformin 850 mg oral tablet bid","MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).",[20,9],null,{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":30},"DIETARY_SUPPLEMENT","Supplemental fiber mixture (35 g total) composed of 6g of Oligofructose + 12g of resistant maltodextrin + 12g of acacia gum + 5g of PGX.","The first week of treatment will use 1\u002F3 the daily treatment dose; then 2\u002F3 dose for the second and third weeks; then the full dose thereafter, to allow time for adaptation.",[15,20],[37],{"name":38,"affiliation":5,"role":39},"Andrea M Haqq, MD, MHS","PRINCIPAL_INVESTIGATOR",[41],{"name":38,"role":42,"phone":43,"phoneExt":30,"email":44},"CONTACT","780-492-0015","haqq@ualberta.ca",[46],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Edmonton","Alberta","T6G 2E1","Canada","CA",{"type":54,"coordinates":55},"Point",[56,57],-113.46871,53.55014,{"lat":57,"lon":56},[60,61],{"name":38,"role":42,"phone":43,"phoneExt":30,"email":44},{"name":38,"role":39,"phone":30,"phoneExt":30,"email":30},{"type":63,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100406917","phase-3-fiber-and-metformin-combination-therapy-in-adolescents-with-severe-obesity-and-insulin-resistance-100406917",false,"NCT04578652","Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance","Fiber Supplementation and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin Resistance: Interactions With the Gut Microbiome.","Inclusion Criteria:\n\n1. Age 12-18 years\n2. BMI percentile \\> 95% for age\u002Fsex;\n3. Total weight fluctuation over past 6 months \\\u003C 10%;\n4. HOMA-IR \\> 3.16;\n5. FH of T2DM (first or second-degree relative).\n\nExclusion Criteria:\n\n1. Current use of insulin or diagnosis of T2DM;\n2. Systolic or diastolic blood pressure (BP) \\> 99th percentile for age and sex;\n3. Acute infectious or inflammatory condition over the preceding 1 month; hospitalization \\> 48 hrs;\n4. History of chronic disease such as inflammatory bowel disease, chronic severe liver or kidney disease or neurologic disorders;\n5. Active malignancy;\n6. Concomitant use of medication\u002Finvestigational drug known to affect body weight in the past year;\n7. Antibiotic use in past 60 days; probiotic and\u002For prebiotic supplements use in the past 30 days; use of lipid-lowering and anti-inflammatory medication.","ALL","12 Years","18 Years",{"count":75,"type":76},90,"ESTIMATED","INTERVENTIONAL",[79],"PHASE3","This is a 12-month, single center, three-arm parallel design, double-blind, randomized clinical trial, to compare the effects of supplemental dietary fiber and metformin (MET) alone and in combination over 12 months on glucose metabolism (insulin resistance \\[IR\\]), inflammation and BMI in adolescents with obesity and IR, and to assess the relationship between therapeutic intervention(s) and changes in gut microbiome composition and function.\n\nSince MET and FIBER have been shown to reduce weight and increase insulin sensitivity through distinct but overlapping mechanisms of action, our central hypothesis is that the combination of FIBER + MET will have a synergistic effect and be more effective than FIBER or MET alone in improving metabolic function (IR) and reducing BMI and inflammation in adolescents with obesity, IR and family history (FM) of T2DM.\n\n.",[82,83],"Obesity, Childhood","Insulin Resistance",[85,86],"Dietary fiber","Metformin","2025-11-14",{"date":89,"type":90},"2025-11-17","ACTUAL",{"date":92,"type":90},"2021-10-22",{"date":94,"type":76},"2026-09",{"name":5,"class":6},1]